The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.

The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.

The present invention relates to lipase variants of the parent lipase shown as SEQ ID NO: 2 with improved wash performance and/or Benefit Risk Factor (BRF). The invention also relates to polynucleotides encoding the lipase variants of the invention, compositions comprising a lipase variant of the invention as well as methods of producing such lipase variants of the invention and the use of the lipase variants or compositions thereof.

The present invention relates to lipase variants of the parent lipase shown as SEQ ID NO: 2 with improved stability during use in a wash process (IWS). The invention also relates to polynucleotides encoding the lipase variants of the invention, compositions comprising a lipase variant of the invention as well as methods of producing such lipase variants of the invention and the use of the lipase variants or compositions thereof.

The present invention relates to lipase variants of the parent lipase shown as SEQ ID NO: 2 with improved wash performance and/or Benefit Risk Factor (BRF). The invention also relates to polynucleotides encoding the lipase variants of the invention, compositions comprising a lipase variant of the invention as well as methods of producing such lipase variants of the invention and the use of the lipase variants or compositions thereof.

The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.

The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.

Lipase enzymes, methods of making lipase enzymes, methods of using lipase enzymes in food, feed, personal care, detergents, grain processing, pulp and paper processing, biofuels, ethanol production, textiles, dairy processing, cocoa butter processing, cocoa extraction, dietary supplements, coffee processing, coatings, water treatment, and oil processing.

A method for removing a stain from a surface using lipase enzymes, and a formulation comprising a lipase enzyme.

The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.